Positive Predictive Value Assessment of Malignancy in BI-RADS 4B and 4C Breast Lesions in Indian Scenario: A Tertiary Center Study

Satish Chaitanya1, Aakriti Kapoor1, Prateek Sharda2, Ananya Deori1, Gangotri Kumari1, Mriganki Chaudhary1, Shalinee Rao1, Anjum Syed2, Bina Ravi1

1Department of Integrated Breast Care Center (IBCC), Senior Resident, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India.
2Department of Integrated Breast Care Center (IBCC), All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India.
3Department of Pathology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India.
4Department of Integrated Breast Care Center (IBCC), All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India.
*Corresponding author: Dr. Satish Chaitanya, Department of Integrated Breast Care Center (IBCC), Senior Resident, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India, E-mail: drksc.123@gmail.com

Abstract

Breast Imaging Reporting and Data System (BI-RADS) is a standardized method of reporting breast pathology identified in breast imaging which is classified into seven categories (0-6) of which category 4 covers a wide range of likelihood of malignancy in between from 2-95% likelihood of malignancy. To improve clinical audits, category 4 is sub-categorized into 4A, 4B, and 4C categories. The positive predictive value for malignancies of BI-RADS 4B and 4C lesions in correlation with pathological diagnosis. This was a retrospective study conducted from June to May 2021 in the Integrated Breast Care Centre (IBCC) in AIIMS, Rishikesh, India. A total of 77 patients were classified as BI-RADS 4B and 4C lesions, 33 were classified as BI-RADS 4B, and 4C as BI-RADS 4C sub-categories.

Keywords: BI-RADS; PPV; Breast; Carcinoma; Biopsy; Pathological techniques

Introduction

Breast disorders are the most commonly diagnosed diseases in females in the present era, especially in India. Hence the evaluation and diagnosis of breast-related problems have progressed significantly over the past 15-20 years due to recent advances in imaging technology and Pathological techniques as well as increased interdisciplinary management of breast problems. "Breast cancer is the most common cancer identified in the Indian women accounting for about 27.7% of all the cancers in Indian women according to Globocan 2018"[1].Breast Imaging Reporting and Data System (BI-RADS) is a standardized method of reporting breast pathology identified in Breast Imaging (Mammography, Ultrasound, and MRI) which is classified into seven categories, from category 0–6 [2]. In this classification, BI-RADS category 4 is reserved for imaging findings that do not have the classic features of malignancy but are sufficient enough to justify a biopsy to rule out malignancy. BI-RADS category 3 represents a less than 2% likelihood of malignancy, while category 5 represents a 95% or more likelihood of malignancy therefore, category 4 covers a wide range of likelihood of malignancy in between from 2-95% likelihood of malignancy [3].To improve clinical audits, inter-communication with surgeons, pathologists, and Image-directed research, many facilities subdivide category 4 into BI-RADS 4A, 4B and 4C especially with 4B and 4C lesions having moderate to high (10-95%) suspicion for malignancy. There are limited studies in the research literature evaluating the positive predictive values and pathological results of 4A, 4B and 4C subcategories [4,5].
Objectives

This study aims to correlate Radiological diagnosis with the Pathological diagnosis of BI-RADS 4B and 4C lesions to assess the positive predictive value for malignancies of BI-RADS 4B and 4C lesions in correlation with pathological diagnosis.

Materials and Methods

This was a retrospective observational study conducted from September 2018 to August 2019 for 12 months in the Integrated Breast Care Centre (IBCC) established exclusively for patients related to breast diseases at AIIMS, Rishikesh in September 2018 in collaboration with other departments like Breast Imaging, Onco-Pathology and Radiation Oncology.

In these 12 months out of a total of 2567 patients, 77 patients were classified as BI-RADS 4B and 4C lesions by Radiologists based on imaging findings of which 33 were classified as BI-RADS 4B and 4C as BI-RADS 4C sub-categories.

Patients who presented to Breast clinic OPD with various complaints underwent triple assessment with a clinical examination followed by radiological assessment with imaging modalities like mammogram and ultrasonography. Based on ACR guidelines, ultrasonography was performed for patients <35 years, and a mammogram was performed in patients >35 years of age. Complimentary mammography or ultrasonography was done when needed. The imaging features were analyzed accordingly and classified 0 to 6.

Ultrasonogram was performed using high-frequency (4-12 MHz) linear probe of Esaote MyLab 9 eXP Diagnostic Ultrasound System, Model: MyLab Nine eXP scanner, and Mindray Z6. Mammography was performed using Hologic Selenia Dimensions, Hologic (USA).

Patients who were identified with breast lesions of BI-RADS category 4 and above on imaging underwent pathological assessment (FNAC and Trucut Biopsy with 14 Gauge needle) after informed consent. All the procedures were performed under image guidance by experienced radiologists. Pathology reports were issued by two senior pathologists with significant experience in breast pathology. Patients who had not given consent for procedures and lesions categorized 0, 1, 2, 3; 4A and 5 were excluded from our study.

The radiological diagnosis was analyzed in correlation with pathological diagnosis to establish the positive (PPV) for malignancy in BI-RADS 4B and 4C breast lesions.

Statistical analysis

Our statistical analyses were performed using the SPSS software package version 26. All continuous and categorical variables were assessed for the values normal distribution. The descriptive data were given as means ± SD. The Pearson chi-square test was used for the analytic assessment and the differences were considered to be statistically significant when the p-value was <0.05. Calculations were done by simple percentage and Positive Predictive Value (PPV) was calculated by the formula:

\[ \text{PPV} = \frac{\text{True positive}}{\text{Total positive}} \times 100 \]

Summary of concordance analysis

- Fleiss Kappa (Concordance between all 3 taken together)=0.544 (p<0.001)
- Cohen’s Kappa (For Pairwise Concordance):
  - FNAC with Biopsy: Kappa=0.867, p<0.001
- Kappa value interpretation Landis and Koch (1977):
  - <0 : No agreement
  - 0-0.20 : Slight
  - 0.21-0.40 : Fair
Results

Of all patients included in this study, the Mean+SD of age in patients with BI-RADS 4B lesions was 42.97 ± 13.99 and 4C lesions were 47.82 ± 10.93 respectively (4C>4B). Family or past surgical history related to malignancy was noted in 14 (42.4%) and 10 (22.7%) of patients with 4B and 4C lesions. The Mean+SD duration of complaints was around 11.44 ± 11.63 months and 7.72 ± 11.39 months in patients with BI-RADS 4B and 4C lesions respectively noting more duration of symptoms noted in patients with 4B lesions. On clinical examination, a lump in the breast was noted in 29 (87.9%) and 41 (93.2%) of patients with BI-RADS 4B and 4C lesions respectively. The Mean+SD size of the lump palpable in BI-RADS 4B and 4C lesions was 3.36 ± 1.43 cm and 9.17 ± 14.00 cm respectively. (Tables 1 and 2).

There was a significant difference between the various groups in terms of the distribution of Biopsy (X^2=18.827, p=<0.001).

In the BI-RADS 4B group, 69.7% and 30.3% proved to be benign and malignant, respectively on biopsy. Similarly in the BI-RADS 4C group, 20.5% and 79.5% of the participants proved benign and malignant on biopsy respectively as in Table 3.

There was a near perfect agreement between the two methods, and this agreement was statistically significant (Cohen's Kappa=0.867, p=<0.001) as in Table 4.

The disagreements observed between the two methods were as follows

2 (2.6%) cases classified as benign by biopsy, were classified as malignant by FNAC. 3 (3.9%) cases classified as malignant by biopsy were classified as benign by FNAC. In the cases which came as benign on biopsy however malignant on FNAC, a repeat biopsy was done using VABB, which also showed benign pathology, hence they were kept on short-term follow-up. The lesions which came malignant on core biopsy and benign on FNAC were treated like malignant lesions.

DISCUSSION

The Breast Imaging-Reporting and Data System (BI-RADS) was developed in the year 1985 to standardize breast lesions reporting on imaging and follow-up [6]. Each abnormality in the breast is assessed systematically correlating with the patient's history and imaging findings finally into 6 BI-RADS categories. BI-RADS 4 category assigned to suspicious lesions, for which, there is a 2 to 95% likelihood of malignancy. A biopsy is routinely recommended in these cases. Therefore, in the ACR BI-RADS atlas, the suggestion now is to subdivide category 4 into three subgroups (4A, 4B and 4C) to better inform the referring surgeons and pathologists of the degree of concern. These subcategories also serve to accomplish a more informative internal audit, to improve radiological/pathological correlation, and image-directed research.

Out of all BI-RADS categorized lesions, category 4B is appropriate for lesions considered to have a moderate (10-50%) suspicion, and the 4C category has high (50-95%) suspicion of malignancy. These lesions are further subjected to biopsy for confirmation of the type of lesion which influences the treatment modality to the patient. Follow-up and correlation of pathological results are of the greatest importance in this subgroup because the range of lesion types may be fairly evenly distributed between benign and malignant, which in turn change the fate of these patients.

According to ACR guidelines, positive predictive values for BI-RADS 4 lesions are 2-95% for malignancy, of which 10-50% PPV for BI-RADS 4B lesions and 50-95% PPV for BI-RADS 4C lesions [7]. In a study of 186 BI-RADS 4 lesions, where 73 (39%) of them were histologically proven for malignancy, the appearance of subcategories 4A, 4B and 4C were 19.5%, 41.5%, and 74.3%, respectively[8]. In another study, 2,430 patients with BI-RADS 4 lesions who were subjected to biopsy, found a prevalence of 18.6% of cancer. The PPV for cancer was 7.6% for BI-RADS 4A lesions, 37.8% for 4B and 81.9% for 4C lesions.
These findings were found to be comparable with our findings [9]. In a study, they found positive predictive values for malignancy in the categories as follows: BI-RADS 2: 0%, 3: 2%, 4: 30%, 5: 97%[10]. In our study, we observed Positive Predictive Values (PPV) similar to other studies. 30.3% of the participants in the group BI-RADS 4B had biopsy malignant and 79.5% of the participants in the group BI-RADS 4C had biopsy malignant as in (Figures 1 and 2). This was per the recommended ACR guidelines.

It was found that other diagnoses excluding malignancy in BI-RADS 4B lesions were 7(30.4%) phyllodes tumor, 9(27.2%) fibro adenoma, 1(4.34%) fibrocystic disease, 1(4.34%) fibro adenomas, 2(6.06%) granulomatous mastitis and 3(9.09%) inflammatory conditions. Similarly, 3(6.81%) cases were found to be phyllodes tumor, 2(4.54%) fibrocystic disease, 2(4.54%) granulomatous mastitis, and 2(4.54%) inflammatory conditions observed in BI-RADS 4C breast lesions. These conditions can mimic malignancy on imaging which will lead to false positivity diagnosis on imaging.

Discordant benign are those lesions that have imaging features highly suspicious for malignancy but results in benign pathology on core biopsy as in Figure 3. The reported percentages of imaging-pathology discordant lesions among breast CNB in the literature range from 2 to 19.2% [11-15]. Benign lesions with speculated findings (granul cell tumor, sclerosing adenosin, postsurgical scar, fat necrosis, mastitis, diabetic mastopathy, and sarcoidosis) can mimic malignancy on imaging [16-17]. However, approximately 4 to 30.9% of discordant lesions after USG guided biopsy are confirmed as cancer by subsequent surgical excision as in Figure 4 [14,15].

If there is concern regarding a discordant benign core biopsy, the radiologist needs to discuss with the interpreting pathologist and communicate about the discrepancy in both diagnoses. Based on that discussion, the radiologist should communicate with the referring surgeon, patient, and discuss the need for a repeat biopsy. In addition to surgical biopsy, USG guided VABB is a valuable alternative to surgical biopsy for these discordant lesions and the reported upgrade rate ranges from 4.6% to 22.7% in various studies [18-20]. Therefore, both surgical biopsy and USG guided VABB can be recommended for repeated biopsies of discordant benign lesions at USG guided biopsy, and the best biopsy method for that particular type of lesion should be chosen based on interdepartmental discussions between the radiologist, pathologist, surgeon, and finally with the patient. In our study, we had done similar inter-departmental discussions and alternative procedures like VABB and surgical excisional biopsy were performed based on the feasibility and necessity of these lesions (Figures 5 and 6).

**Conclusion**

The Positive Predictive Value (PPV) for BI-RADS 4B and 4C lesions, found in our study were according to the current ACR guidelines. Hence, sub categorizing these lesions into BI-RADS 4B and 4C was justified in our study. The cause of discordant benignity in our study were various lesions that can mimic malignancy on imaging, such as phyllodes tumor, fibro adenoma, fibrocystic disease, fibroadenomas, granulomatous mastitis, and inflammatory conditions. Hence, the existence of such lesions mimicking malignancy justifies the need of classifying suspicious lesions into BI-RADS 4B and 4C and not into the BI-RADS 3 or 5 categories on imaging.

**References**


Table 1: Pathology details of benign lesions.

<table>
<thead>
<tr>
<th>S.No</th>
<th>Total (77)</th>
<th>4B (33)</th>
<th>4C (44)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Benign</td>
<td>23 (69.7%)</td>
<td>9 (20.5%)</td>
</tr>
<tr>
<td>2</td>
<td>Phyllodes tumor</td>
<td>7 (30.4%)</td>
<td>3 (6.81%)</td>
</tr>
<tr>
<td>3</td>
<td>Fibro adenoma</td>
<td>9 (27.2%)</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>Fibrocystic disease</td>
<td>1 (4.34%)</td>
<td>2 (4.54%)</td>
</tr>
<tr>
<td>5</td>
<td>Granulomatous mastitis</td>
<td>2 (6.06%)</td>
<td>2 (4.54%)</td>
</tr>
<tr>
<td>6</td>
<td>Inflammatory conditions</td>
<td>3 (9.09%)</td>
<td>2 (4.54%)</td>
</tr>
<tr>
<td>7</td>
<td>Fibro adenomas</td>
<td>1 (3.98%)</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 2: Pathology details of malignant lesions.

<table>
<thead>
<tr>
<th>S.No</th>
<th>Total (77)</th>
<th>4B lesion (33)</th>
<th>4C lesion (44)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Malignant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>10 (30.3%)</td>
<td>35 (79.5%)</td>
</tr>
<tr>
<td>(A)</td>
<td>Invasive ductal carcinoma</td>
<td>8 (80%)</td>
<td>28 (80%)</td>
</tr>
<tr>
<td>(B)</td>
<td>DCIS</td>
<td>0</td>
<td>1 (3.57%)</td>
</tr>
<tr>
<td>(C)</td>
<td>Grade 1</td>
<td>1 (12.5%)</td>
<td>2 (7.14%)</td>
</tr>
<tr>
<td>(D)</td>
<td>Grade 2</td>
<td>1 (12.5%)</td>
<td>12 (42.8%)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>6 (75%)</td>
<td>13 (46.4%)</td>
</tr>
<tr>
<td>2</td>
<td>Invasive carcinoma (NST)</td>
<td>1 (10%)</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>Papillary carcinoma</td>
<td>1 (10%)</td>
<td>4 (11.4%)</td>
</tr>
<tr>
<td>4</td>
<td>Malignant phyllodes</td>
<td>0</td>
<td>1 (2.85%)</td>
</tr>
<tr>
<td>5</td>
<td>Mucinous carcinoma</td>
<td>0</td>
<td>1 (2.85%)</td>
</tr>
<tr>
<td>6</td>
<td>Poorly differentiated carcinoma</td>
<td>0</td>
<td>1 (2.85%)</td>
</tr>
</tbody>
</table>

Table 3: Association between BI-RADS and biopsy (n = 77)

<table>
<thead>
<tr>
<th>Biopsy</th>
<th>BIRADS</th>
<th>Chi-Squared Test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4B</td>
<td>4C</td>
</tr>
<tr>
<td>Benign</td>
<td>23 (69.7%)</td>
<td>9 (20.5%)</td>
</tr>
<tr>
<td>Malignant</td>
<td>10 (30.3%)</td>
<td>35 (79.5%)</td>
</tr>
<tr>
<td>Total</td>
<td>33 (100.0%)</td>
<td>44 (100.0%)</td>
</tr>
</tbody>
</table>

Table 4: Comparison of FNAC with biopsy (n = 77)

<table>
<thead>
<tr>
<th>Biopsy</th>
<th>Benign</th>
<th>Malignant</th>
<th>Total</th>
<th>Cohen’s Kappa</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FNAC</td>
<td>30 (39.0%)</td>
<td>3 (3.9%)</td>
<td>33 (42.9%)</td>
<td>0.867</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Malignant</td>
<td>2 (2.6%)</td>
<td>42 (54.5%)</td>
<td>44 (57.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>32 (41.6%)</td>
<td>45 (58.4%)</td>
<td>77 (100.0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1: Association between BI-RADS 4B and 4C lesions with biopsy.

Figure 2: Bar graph depicts the classification of cases by both the methods.
Figure 3: Mammography and USG of BI-RADS 4B lesion (discordant benign).

Figure 4: Greyscale USG image shows a multilobulated, heterogeneously.

Figure 5: Mammography and USG of BI-RADS 4C lesion (concordant malignant).
Figure 6: Mammography and USG of BI-RADS 4C lesion (concordant malignant).